What are the recommended starting doses of cabozantinib for metastatic renal cell carcinoma, advanced hepatocellular carcinoma, and progressive medullary thyroid cancer, and how should the dose be adjusted for hepatic or renal impairment and treatment‑related toxicities?

Cabozantinib Dosing by Indication

The recommended starting dose of cabozantinib varies significantly by indication: 60 mg daily for metastatic renal cell carcinoma (as monotherapy), advanced hepatocellular carcinoma, and differentiated thyroid cancer; 40 mg daily when combined with nivolumab for RCC; and 140 mg daily (capsule formulation only) for progressive medullary thyroid cancer. 1

Standard Dosing by Cancer Type

Metastatic Renal Cell Carcinoma (mRCC)

• Monotherapy: 60 mg orally once daily until disease progression or unacceptable toxicity 1
• Combination with nivolumab (first-line): 40 mg orally once daily, with nivolumab 240 mg IV every 2 weeks or 480 mg IV every 4 weeks for up to 2 years 1
• Both regimens are Category 1 recommendations across all IMDC risk groups 2

Advanced Hepatocellular Carcinoma (HCC)

• 60 mg orally once daily in patients with preserved liver function (Child-Pugh A) who have progressed on sorafenib 1, 3
• This represents second-line therapy with a conditional recommendation given the 2.2-month overall survival benefit 3

Differentiated Thyroid Cancer (DTC)

• Adults and pediatric patients ≥12 years with BSA ≥1.2 m²: 60 mg orally once daily 1, 4
• Pediatric patients ≥12 years with BSA <1.2 m²: 40 mg orally once daily 1
• Indicated for RAI-refractory DTC that progressed on prior VEGFR-targeted therapy 4
• Critical distinction: Use the tablet formulation at 60 mg for DTC 4

Medullary Thyroid Cancer (MTC)

• 140 mg orally once daily using the capsule formulation 4, 5
• This is a Category 1 recommendation for recurrent or persistent MTC 5
• The capsule and tablet formulations are NOT bioequivalent and cannot be substituted 4

Administration Requirements

All cabozantinib doses must be taken on an empty stomach: no food intake for at least 2 hours before and at least 1 hour after taking the drug 4, 1

Dose Modifications for Toxicity

Standard Dose Reduction Schedule

For patients starting at 60 mg daily:

• First reduction: 40 mg daily
• Second reduction: 20 mg daily
• If 20 mg daily is not tolerated, discontinue 1

For patients starting at 40 mg daily (combination therapy or pediatric BSA <1.2 m²):

• First reduction: 20 mg daily
• Second reduction: 20 mg every other day
• If not tolerated, discontinue 1

When to Withhold or Reduce Dose

Withhold cabozantinib for:

• Intolerable Grade 2 adverse reactions
• Grade 3 or 4 adverse reactions
• Osteonecrosis of the jaw 1

Permanently discontinue for:

• Grade 3 or 4 hemorrhage
• Any grade gastrointestinal perforation or Grade 4 fistula
• Severe thrombotic events 1

Resume at reduced dose once adverse reactions resolve to baseline or Grade 1 1

Common Toxicities Requiring Management

The most frequent adverse events necessitating dose reduction include:

• Palmar-plantar erythrodysesthesia (hand-foot syndrome): 10% Grade 3/4 4
• Hypertension: 9% Grade 3/4 4
• Fatigue: 8% Grade 3/4 4
• Diarrhea, mucositis, and weight loss 6

In the COSMIC-311 trial for DTC, 56% of patients required initial dose reduction and 22% required secondary reduction, with only 5% discontinuing due to toxicity 4

Dosing in Hepatic and Renal Impairment

Hepatic Impairment

Mild to moderate hepatic impairment (Child-Pugh A or B):

• Cabozantinib AUC increases by 63-81% 7
• Use with caution and monitor closely for treatment-emergent toxicity that may require dose holds or reductions 7
• No specific dose adjustment provided in FDA labeling, but clinical judgment suggests starting at reduced dose (40 mg) may be prudent 1

Severe hepatic impairment: Not studied; use is not recommended 1

Renal Impairment

Mild to moderate renal impairment:

• Cabozantinib AUC increases by 7-30% 7
• Use with caution but no specific dose adjustment required 7
• Monitor closely for adverse events 1

Severe renal impairment or dialysis: Not adequately studied 1

Critical Clinical Considerations

Formulation Differences

This is a critical safety issue: The 140 mg capsule formulation (for MTC) and the 60 mg tablet formulation (for RCC, HCC, DTC) are NOT bioequivalent and must never be substituted for one another 4, 1. Prescribers must specify the correct formulation for the indication.

Surgical Planning

Stop cabozantinib at least 3 weeks before any scheduled surgery, including dental procedures, due to risks of impaired wound healing, hemorrhage, and osteonecrosis of the jaw 1

Drug Interactions

• Strong CYP3A4 inhibitors (e.g., ketoconazole): Increase cabozantinib AUC by 34-38%; consider dose reduction 8
• Strong CYP3A4 inducers (e.g., rifampin): Decrease cabozantinib AUC by 76-77%; avoid concomitant use 8
• High-fat meals: Increase cabozantinib AUC by 57%; maintain fasting requirements 8

Real-World Dosing Patterns

In clinical practice, approximately 68% of patients require dose reduction from the starting 60 mg dose or begin at a reduced dose without escalation 9. Interestingly, some real-world data suggest that alternative (intermittent) dosing schedules may improve both tolerability and efficacy compared to continuous dosing, though this requires prospective validation 10.

Concentration-Response Relationships

Emerging data suggest that serum cabozantinib concentrations correlate with both tumor response and adverse events 11. The occurrence of specific toxicities like hand-foot syndrome and hypertension may serve as pharmacodynamic markers of adequate drug exposure and are associated with improved outcomes 9, 11.